文献速递细菌感染、耐药与抗菌药物

临床来源尿路致病性大肠埃希菌分离株中呋喃妥因耐药性的原位进化探索

Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

研究基于AnTIC试验中17例清洁间歇自我导尿患者的尿路致病性大肠埃希菌分离株,探索呋喃妥因耐药性的原位进化。生长率分析显示耐药株倍增时间较敏感株慢2%-10%,未显示进化株相比敏感前代株的适应性优势(P=0.13)。作者认为社区中大肠埃希菌呋喃妥因耐药低发生率由尿液中呋喃妥因浓度选择性抑制携带关键第一步功能丧失突变菌株生长所驱动。

要点

  • 呋喃妥因耐药株倍增时间较敏感株慢2%-10%,未显示适应性优势(P=0.13)。
  • 遗传操作模拟耐药进化亦未显示适应性优势(P=0.22)。
  • 第一步突变体在亚MIC(4-8 mg/L)呋喃妥因浓度下获得选择性优势。

核心结论

  • 研究结果与呋喃妥因药代动力学数据的关联提示,社区中大肠埃希菌呋喃妥因耐药低发生率由尿液中呋喃妥因浓度选择性抑制携带关键第一步功能丧失突变菌株的生长所驱动。

研究设计与样本

  • 研究分析参加AnTIC试验的17例患者的尿路致病性大肠埃希菌分离株,该试验为12个月开放标签随机对照试验,评估抗生素预防降低清洁间歇自我导尿患者尿路感染发生率的疗效。
  • 采用通用微生物学技术和遗传学方法模拟已知呋喃妥因耐药突变。

主要发现

  • 生长率分析显示呋喃妥因耐药株倍增时间较敏感株慢2%-10%:敏感株为20.8±0.7分钟,耐药株为23±0.8分钟。
  • 统计学分析表明进化株相比敏感前代株无适应性优势(P=0.13)。
  • 遗传操作模拟呋喃妥因耐药进化亦未显示适应性优势(P=0.22)。
  • 数据表明第一步突变体在亚MIC(4-8 mg/L)呋喃妥因浓度下获得选择性优势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nitrofurantoin has been re-introduced as a first-choice antibiotic to treat uncomplicated acute urinary tract infections in England and Wales. Highly effective against common uropathogens such as Escherichia coli, its use is accompanied by a low incidence (<10%) of antimicrobial resistance. Resistance to nitrofurantoin is predominantly via the acquisition of loss-of-function, step-wise mutations in the nitroreductase genes nfsA and nfsB. OBJECTIVE: To explore the in situ evolution of NitR in E. coli isolates from 17 patients participating in AnTIC, a 12-month open label randomized controlled trial assessing the efficacy of antibiotic prophylaxis in reducing urinary tract infections (UTIs) incidence in clean intermittent self-catheterizing patients. METHODS: The investigation of NitR evolution in E. coli used general microbiology techniques and genetics to model known NitR mutations in NitSE. coli strains. RESULTS: Growth rate analysis identified a 2%-10% slower doubling time for nitrofurantoin resistant strains: NitS: 20.8 ± 0.7 min compared to NitR: 23 ± 0.8 min. Statistically, these data indicated no fitness advantage of evolved strains compared to the sensitive predecessor (P-value = 0.13). Genetic manipulation of E. coli to mimic NitR evolution, supported no fitness advantage (P-value = 0.22). In contrast, data argued that a first-step mutant gained a selective advantage, at sub-MIC (4-8 mg/L) nitrofurantoin concentrations. CONCLUSION: Correlation of these findings to nitrofurantoin pharmacokinetic data suggests that the low incidence of E. coli NitR, within the community, is driven by urine-based nitrofurantoin concentrations that selectively inhibit the growth of E. coli strains carrying the key first-step loss-of-function mutation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Vallée M, Harding C, Hall J, et al. Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates. J Antimicrob Chemother. 2023. PMID: 36480295. doi:10.1093/jac/dkac398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。